Brain-Targeting Chemical Delivery Systems and Their Cyclodextrin-Based Formulations in Light of the Contributions of Marcus E. Brewster

Abstract

Here, we present a brief review of brain-targeting chemical delivery systems (CDSs) and their cyclodextrin-based formulations. It is dedicated to the memory of Marcus E. Brewster (1957-2014) and highlights those aspects where he made particularly valuable contributions. During the first two decades of his scientific career that were dedicated to these fields (1978-1997), Marcus was involved in the development of several brain-targeted redox compounds, including design, activity assays, physicochemical characterization, computational modeling of theoretical aspects, and development of cyclodextrin-based formulation for increased stability and water solubility, as well as preclinical and clinical testing. CDSs are designed to provide site-specific or site-enhanced delivery through sequential, multistep enzymatic, and chemical transformations. Brain-targeting CDSs incorporate a redox targetor that undergoes enzymatic transformation resulting in a drastic change in physicochemical properties. They can not only increase central nervous system access by making the molecule more lipophilic and enabling its diffusion through the blood-brain barrier, but they can also provide more sustained release by "locking" it behind the blood-brain barrier by subsequently converting it into a hydrophilic intermediate. The origins of the concept (Pro-2-PAM, berberine), one of the most important representative (estradiol-CDS), and the introduction of 2-hydroxypropyl-β-cyclodextrin for improved formulations are discussed in detail.

Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases

“…Although all types of CDs can achieve inclusion complexes, the size of their inner cavity represents the main concern as to which CD can display better success in complex formation. To this aim, of the three native CDs, β-CDs have been shown to exhibit the most suitable cavity size for hosting many biological compounds such as hormones, vitamins, and other molecules frequently used in the biology field [17].…”

Multifunctional LUV liposomes decorated for BBB and amyloid targeting - B. In vivo brain targeting potential in wild-type and APP/PS1 mice

“…The blood-brain barrier (BBB) protects neurons and preserves the CNS, but at the same time prevents drug entry in the CNS (Pardridge, 2016), generating a huge challenge for theragnosis of brain-located pathologies, as Alzheimer's disease (AD). Several noninvasive approaches using nano-particulate carriers have been proposed to overcome this challenge, and some have been successful to delivery higher amounts of drugs (compared to free drug) to the brain (Lalani et al 2012;Wong et al, 2012;Aparicio-Blanco et al 2016; Buchwald and Bodor, 2016;Fu et al 2016;Gutkin et al 2016;Nair et al 2016;Saraiva et al 2016;Tam et al 2016;Zhang et al 2016). Recently, liposomes (LIPs) with one ligand to target the transferrin receptor and another to target the low-densityapolipoprotein receptor (LDLr), were demonstrated to have increased BBB targeting capability, compared to LIPs with one ligand (Markoutsa et al 2014).…”

Interleukin-6: Molecule in the Intersection of Cancer, Ageing and COVID-19

“…In particular, poorly soluble ones suffer from insufficient selectivity for the target organs and tissues, and their half-life in the blood is short. Currently, numerous suitable drug delivery systems for these types of compounds are being developed or are already available, for example, cyclodextrins, silica nanoparticles, and liposomes [155][156][157]. Notably, these systems can be successfully used for drug transport across the blood-brain barrier.…”